Literature DB >> 22937487

Autoimmune diseases and venous thromboembolism: a review of the literature.

Bengt Zöller, Xinjun Li, Jan Sundquist, Kristina Sundquist.   

Abstract

Venous thromboembolism (VTE) is major health problem and is sometimes complicated by lethal pulmonary embolism (PE). Disturbances of the coagulation and anticoagulation systems are important risk factors for VTE. Comparative studies suggest that coagulation and innate immunity have a shared evolutionary origin. It is therefore unsurprising that the immune and coagulation systems are linked, with many molecular components being important for both systems. Systemic inflammation modulates thrombotic responses by suppressing fibrinolysis, upregulating procoagulant, and downregulating anticoagulants, and autoimmune disorders such as systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and Behçet's syndrome have been linked to an increased risk of VTE. Recent reports have further shown that a majority of autoimmune and immune-mediated disorders are linked to an increased risk of venous thrombosis, PE, or VTE. For instance, a Swedish nationwide study found that the risk of PE was increased in the first year after hospitalization for 33 different autoimmune disorders. Especially high risks were noted for several autoimmune diseases such as immune thrombocytopenic purpura, polyarteritis nodosa, polymyositis/dermatomyositis, ulcerative colitis, and SLE. Another study from England, also based on hospitalization data, found that immune-mediated disorders were associated with an increased risk of VTE compared with other medical causes of hospitalization. Multiple mechanisms may operate and disease-specific factors, such as cardiolipin antibodies, have been identified. However, inflammation by itself appears to change the hemostatic balance in a thrombogenic direction. Recent epidemiological studies, together with previous experimental and clinical studies, indicate that autoimmune disorders should not only be viewed as inflammatory disorders, but also hypercoagulable disorders. Research to identify thrombotic risk factors, elucidate the mechanisms involved, and investigate prophylactic regiments is needed. The present review describes the epidemiological, clinical, and experimental evidence for the connection between VTE and autoimmune and immune-mediated disorders.

Entities:  

Keywords:  Autoimmune diseases; blood coagulation disorders; immunology; inflammation; inflammatory bowel diseases; pulmonary embolism; rheumatic diseases; venous thromboembolism; venous thrombosis

Year:  2012        PMID: 22937487      PMCID: PMC3427982     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  116 in total

1.  Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.

Authors:  S Schulman; P Lindmarker; M Holmström; G Lärfars; A Carlsson; P Nicol; E Svensson; B Ljungberg; S Viering; S Nordlander; B Leijd; K Jahed; M Hjorth; O Linder; M Beckman
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

3.  Prevalence of the antiphospholipid syndrome in primary systemic vasculitis.

Authors:  J D Rees; S Lança; P V Marques; J A Gómez-Puerta; R Moco; C Oliveri; M A Khamashta; G R V Hughes; D P D'Cruz
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

4.  Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus.

Authors:  Erika R Chang; Christian A Pineau; Sasha Bernatsky; Carolyn Neville; Ann E Clarke; Paul R Fortin
Journal:  J Rheumatol       Date:  2006-07-01       Impact factor: 4.666

Review 5.  Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.

Authors:  Zheng Ye; Eugene H C Liu; Julian P T Higgins; Bernard D Keavney; Gordon D O Lowe; Rory Collins; John Danesh
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

Review 6.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

7.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.

Authors:  B Zöller; B Dahlbäck
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

8.  Myocardial infarction associated with homozygous resistance to activated protein C.

Authors:  J Holm; B Zöller; P J Svensson; E Berntorp; L Erhardt; B Dahlbäck
Journal:  Lancet       Date:  1994-10-01       Impact factor: 79.321

Review 9.  Inflammation and the activated protein C anticoagulant pathway.

Authors:  Charles T Esmon
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

10.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.

Authors:  Liam Smeeth; Claire Cook; Sara Thomas; Andrew J Hall; Richard Hubbard; Patrick Vallance
Journal:  Lancet       Date:  2006-04-01       Impact factor: 79.321

View more
  45 in total

1.  Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.

Authors:  Hussain R Yusuf; W Craig Hooper; Scott D Grosse; Christopher S Parker; Sheree L Boulet; Thomas L Ortel
Journal:  Thromb Res       Date:  2014-10-22       Impact factor: 3.944

2.  Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study.

Authors:  Melissa Mei Hsia Chan; Akshay S Thomas; Stephen P Yoon; Diana Leitner; Sharon Fekrat
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-07-01       Impact factor: 1.300

Review 3.  The role of neutrophils in thrombosis.

Authors:  Sargam Kapoor; Aman Opneja; Lalitha Nayak
Journal:  Thromb Res       Date:  2018-08-09       Impact factor: 3.944

4.  Assessment of hemostatic disturbances in women with established rheumatoid arthritis.

Authors:  Aleksandra Vranic; Iva Pruner; Mirjana Veselinovic; Nida Soutari; Anica Petkovic; Vladimir Jakovljevic; Aleksandra Antovic
Journal:  Clin Rheumatol       Date:  2019-06-17       Impact factor: 2.980

Review 5.  Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis.

Authors:  Young Ho Lee; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2017-05-10       Impact factor: 2.631

6.  Functional characterization of CXCR4 in mediating the expression of protein C system in experimental ulcerative colitis.

Authors:  Xuhong Lin; Huichao Wang; Yuxia Li; Jingnan Yang; Ruilin Yang; Dandan Wei; Junjie Zhang; Desheng Yang; Bin Wang; Xuequn Ren; Guanchang Cheng
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 7.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

8.  Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Authors:  Hussain R Yusuf; W Craig Hooper; Michele G Beckman; Qing C Zhang; James Tsai; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 9.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

Review 10.  Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases.

Authors:  Melissa Cunningham; Natalia Marks; April Barnado; Jena R Wirth; Gary Gilkeson; Margaret Markiewicz
Journal:  Semin Thromb Hemost       Date:  2014-08-31       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.